Comparison of the direct effect of walking and resistant training

Completed

• Conditions: Low bone mass; Musculoskeletal Diseases; ow bone mass

• Registration Number: ISRCTN16329455
• Lead Sponsor: niversity of Pécs

Brief Summary

2016 results in: https://www.ncbi.nlm.nih.gov/pubmed/27278385

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2015-11-15
• Study Start: 2016-05-05
• Last Update Posted: 19 March 2018

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 150

Inclusion Criteria

1. Female
2. Aged between 35 and 65 years
3. New diagnosis of osteoporosis/osteopenia
4. Lack of endocrine or metabolic disease which would have an impact on bone mineral density or musculoskeletal system
5. Normal lifestyle and activity
6. Agreement to participate
7. Generally considered to be healthy

Exclusion Criteria

1. Any condition influencing calcium and bone metabolism (except dietary calcium and Vitamin D supplementation),
2. Ongoing hormone replacement therapy
3. Any known endocrine/metabolic, renal, or hepatic disease (e.g., hypogonadism, hyperthyroidism, hyperparathyroidism, or increased glucocorticoid levels)
4. Any physical injury (orthopedic, rheumatologic) hindering the performance of physical activity
5. Osseous fracture of any origin during the previous 6 months
6. A diagnosis of cardiovascular disease or uncontrolled hypertension
7. Any non-antibiotic medication within the past year, including steroids of any type, thyroid hormones, diuretics, or anticoagulants
8. Any antibiotic use within the last 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Bone-specific alkaline phosphatase (BALP) concentration is measured using a photometric assay at baseline and immediately after the intervention<br>2. Carboxy-terminal cross-linked telopeptide of type I collagen (CTX) concentration is measured using an electrochemiluminescence immunoassay (ECLIA) at baseline and immediately after the intervention<br>3. Serum sclerostin concentration is measured using a qualitative sandwich enzyme-linked immunosorbent assay (ELISA) at baseline and immediately after the intervention<br><br>Several assistants performed sample collection simultaneously to ensure rapid collection within 0 –5 minutes after the exercise sessions.

Secondary Outcome Measures

Name	Time	Method
Bone mineral density (BMD) is determined by dual energy X-ray absorptiometry (DEXA) using a LUNAR DPX densitometer at baseline.